Evidence-informed educational review. Updated 10 November 2026. Follow current local product labeling and individualized clinical guidance.
For a gastric or duodenal ulcer, drug treatment has two jobs: allow the mucosa to heal and remove the cause of injury. Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes and can coexist. Ask specifically about nonprescription ibuprofen, naproxen and aspirin. Haematemesis, black tarry stools with weakness, or sudden severe abdominal pain require urgent assessment for bleeding or perforation. [1, 2]
Core drug classes
- PPIs: omeprazole, pantoprazole and related drugs irreversibly inhibit gastric H+/K+-ATPase and promote ulcer healing.
- H2-receptor antagonists: famotidine reduces histamine-mediated acid secretion, but PPIs are generally preferred for substantial ulcer healing and prophylaxis in high-risk NSAID use.
- Potassium-competitive acid blockers: vonoprazan blocks the gastric proton pump reversibly through potassium-site competition and is incorporated into some approved H. pylori regimens, depending on country.
- Protective agents: sucralfate adheres to damaged mucosa but does not eradicate H. pylori; misoprostol is a prostaglandin E1 analogue that reduces NSAID ulcer risk but causes diarrhea and is contraindicated for ulcer prevention during pregnancy.
- Antacids: neutralize existing acid for short-term symptomatic relief, but do not replace definitive treatment [3].
When H. pylori is present
For a treatment-naive adult in North America when antibiotic susceptibility is unknown, the 2024 ACG guideline favours 14 days of optimized bismuth quadruple therapy. It combines a PPI, bismuth, tetracycline and metronidazole. Review allergies, previous antibiotic exposure and the patient’s ability to follow the dosing schedule. Clarithromycin- and levofloxacin-containing regimens should be reserved for susceptible strains. Local resistance, availability and previous treatment affect regimen selection. [4, 5]
Arrange a test of cure for every treated patient. A urea breath test, stool antigen test or appropriate biopsy-based test can demonstrate persistent infection. Wait at least four weeks after completing antibiotics and bismuth, and withhold PPIs or potassium-competitive acid blockers for two weeks before testing to reduce false negatives. Symptom relief alone cannot confirm eradication. [4, 5]
NSAID-associated ulcer and prevention
Stop the offending NSAID when feasible. NICE recommends a full-dose PPI or an H2-receptor antagonist for eight weeks in patients with an NSAID-associated peptic ulcer, with H. pylori eradication if infection is present. When continued anti-inflammatory therapy is essential, reassess the indication, dose and need for ongoing gastroprotection. Review aspirin prescribed for cardiovascular prevention separately with the treating clinician. [6, 1]
Misoprostol, a prostaglandin analogue, can reduce NSAID-induced gastric ulcer risk in selected high-risk patients. Cramping and diarrhoea can limit adherence. It can cause uterine contractions and pregnancy loss and is contraindicated during pregnancy for NSAID-ulcer prevention. Antacids may briefly relieve discomfort but do not eradicate H. pylori or provide equivalent ulcer prevention. [7, 1]
A bleeding ulcer follows a different pathway
A patient with suspected significant upper gastrointestinal bleeding needs resuscitation and timely endoscopic assessment. After successful endoscopic haemostasis of a high-risk bleeding ulcer, ACG recommends high-dose PPI for three days, followed by oral PPI twice daily through the first two weeks after endoscopy. Recurrent bleeding warrants reassessment and usually repeat endoscopy. Before discharge, address H. pylori and the medicines that contributed to bleeding. [2, 4, 1]
References
- National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for peptic ulcers (stomach or duodenal ulcers). [cited 2026 Nov 10]. View source.
- Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021;116:899–917. [cited 2026 Nov 10]. View source.
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;119:1730–1753. [cited 2026 Nov 10]. View source.
- American College of Gastroenterology. Guideline highlights: treatment of Helicobacter pylori infection. 2024. [cited 2026 Nov 10]. View source.
- National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. CG184. [cited 2026 Nov 10]. View source.
- National Library of Medicine. Cytotec (misoprostol) tablets. DailyMed prescribing information. [cited 2026 Nov 10]. View source.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.